HIGHLIGHTS
- who: Francesca Mancini and colleagues from the GSK Vaccines Institute for Global Health (GVGH), via Fiorentina, Siena, Italy have published the article: Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent Vaccine against Shigella, in the Journal: (JOURNAL)
- what: The authors show that a quadrivalent Shigella GMMA-based vaccine is able to promote a humoral response against OAg and proteins of all GMMA types contained in the investigational vaccine. This study showed that, when tested in the animal model, GMMA combines both adjuvant and carrier activities, which allows for an increase . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.